On behalf of the European Society of Hyperthermic Oncology (ESHO) and the Deutsche Gesellschaft für Hyperthermie (DGHT) it is our priviledge and great pleasure to invite you to join us for the 32st annual meeting of the European Society of Hyperthermic Oncology (ESHO 2018), which will be held in Berlin, Germany in Mai 16 – 19, 2018.
Berlin is the capital of Germany as well as its largest city and a popular destination for professionals as well as tourists. The city is known for its distinctive history, modern economy, diverse architecture and high quality of living. As the ESHO 2018 meeting takes place during early summer, the city will be alive with a cosmopolitan mix of people and events.
The scientific focus of the ESHO 2018 meeting will be „multimodal treatment of abdominal tumors involving thermal therapy - potential and caveats.“ A line-up of world class speakers as well as interdisciplinary congress sessions will contribute to attract clinicans from various oncological specialities and from around the world. Additionally, the meeting will feature Educational Sessions which will offer separate CME credits.
We look forward to seeing you in Berlin!
Prof. Dr. med. Dr. h.c. Volker Budach
Prof. Dr. med. Peter Wust
PD. Dr. med. Pirus Ghadjar
Dear ESHO 2018 Participants,
Hyperthermia is a key therapy option for the treatment of solid tumors involving both the destruction of neoplastic cells via thermal ablation as well as the use of moderate temperatures to improve effectiveness of both radiation and chemotherapy.
Research and clinical application of hyperthermia techniques have been widely employed at the Charité - Universitätsmedizin for over three decades with the current Charité Hyperthermia Unit based at the Department of Radiation Oncology at our Virchow Campus. The Charité thus serves as a highly active hyperthermia-center, successfully securing substantial third-party funding whilst maintaining high scientific output. In addition, the establishment of national and international interdisciplinary collaborations within the fields of physics and biology as well as in numerous further clinical disciplines including gynecology, radiology and pediatric oncology is one of our foremost strengths. Current scientific activity focuses on technological, biological and translational research as well as the conduction of innovative clinical trials. Such exploration is essential in order to achieve greater understanding of the underlying biological mechanisms involved in using hyperthermia for cancer treatment. Furthermore, research results generate additional evidence, which will inevitably lead to indication range extension for further tumor entities. This is particularly relevant in cases where standard treatments have proven unsatisfactory (e.g. abdominal tumors).
It is therefore with great pleasure that we welcome the world’s leading hyperthermia experts to Berlin for the ESHO 2018. The conference has been organized in cooperation with the European Society for Radiotherapy & Oncology (ESTRO) and is endorsed by relevant national organizations as well as the European Cancer Organization (ECCO) and the European Society of Surgical Oncology (ESSO).
I am confident that the ESHO 2018 will serve as an excellent scientific exchange platform thus facilitating the advancement of hyperthermia research and improved clinical treatment.
Charité - Universitätsmedizin Berlin
To foster innovations and to advance the speed of translation of those innovations to medical practice are core elements of the mission of the Berlin Institute of Health (BIH). We encourage the clinical and basic research community in Berlin to join forces to tackle this goal in an interdisciplinary and systemic approach. And – by establishing Berlin Health Innovations, the joint technology transfer initiative of BIH and Charité – we support inventors to deliver their ideas and concepts to markets and patients. ESHO and ESTRO are both societies with a translational mission very similar to the BIH mission. I am very happy that both societies choose Berlin for their annual meeting in 2018 and I wish the organizers and all attendees exciting days full of scientific interaction within their respective research communities and the local faculties.
Enjoy your annual meetings and
all the best,
Chief Financial Officer
A warm welcome to all of the participants in the 32nd Annual Meeting of the European Society for Hyperthermic Oncology!
Your annual meeting is focused on a cutting-edge method used to treat cancer. Because this treatment can lead to significant improvements in quality of life and the chance of recovery, many patients are pinning their hopes on the use of hyperthermia. That makes it all the more important that great effort continue to be expended on researching and applying this promising treatment method in the fight against cancer. Regular international exchange of the kind you cultivate at the ESHO meetings is absolutely essential to this endeavor.
I am delighted that leading experts in this field are meeting here in Berlin this time to discuss new findings and hands-on experience with hyperthermia.
With its many renowned research and treatment institutions and its eminent university medical facilities, the health capital Berlin offers you an ideal setting for a successful annual meeting. Your host, Charité-Universitätsmedizin Berlin, has many years of experience with hyperthermia, for instance, and its clinic for radiation oncology and radiation therapy is one of today’s foremost hyperthermia centers worldwide. As a result, I am confident that you will feel at home here in Berlin.
With this in mind, I would like to wish you a very productive 2018 ESHO Annual Meeting. I hope that those of you coming from outside Germany’s capital city will have a very pleasant stay that is a source of new inspiration when you return home. My thanks go to the European Society for Hyperthermic Oncology and the European Society for Radiotherapy and Oncology for choosing Berlin as the venue for this prestigious gathering.
Governing Mayor of Berlin